Bimezumab, an antibody that neutralizes IL-17A homodimers and IL-17A-IL-17F heterodimers (234), achieved Psoriasis size and severity index (PASI)-(PASI is a measure of psoriasis lesion area BSA + psoriasis lesion severity, Mild: skin lesions <3% of the area; Moderate: skin lesion area 3%~10% BSA; Severe: skin lesion area >10% BSA). Here, IL17F is linked to psoriasis.